| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
40,010,000 |
| Market
Cap: |
862.62(M) |
| Last
Volume: |
1,008,943 |
Avg
Vol: |
1,006,153 |
| 52
Week Range: |
$12.64 - $30.11 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cassava Sciences is a clinical-stage biotechnology company. Co. has combined technology with insights in neurobiology to develop solutions for Alzheimer's disease and other neurodegenerative diseases. Co. has two biopharmaceutical assets under development: its primary therapeutic product candidate, called simufilam, is a treatment for Alzheimer's disease; and its primary investigational diagnostic product candidate, called SavaDx, is a way to detect the existence of Alzheimer's disease from a small sample of blood.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
48,477 |
278,477 |
| Total Buy Value |
$0 |
$0 |
$831,428 |
$6,164,449 |
| Total People Bought |
0 |
0 |
2 |
4 |
| Total Buy Transactions |
0 |
0 |
3 |
9 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Barbier Remi |
CEO, Chairman of the Board |
• • • |
2014-07-14 |
4 |
D |
$5.09 |
$1,949,373 |
D/D |
(382,981) |
4,369,731 |
|
- |
|
| Barbier Remi |
CEO, Chairman of the Board |
• • • |
2014-07-14 |
4 |
OE |
$4.54 |
$1,947,574 |
D/D |
428,981 |
4,752,359 |
|
- |
|
| Schoenhard Grant |
Chief Scientific Officer |
• – – |
2014-07-11 |
4 |
D |
$4.98 |
$584,269 |
D/D |
(117,323) |
78,551 |
|
- |
|
| Schoenhard Grant |
Chief Scientific Officer |
• – – |
2014-07-11 |
4 |
OE |
$4.54 |
$584,266 |
D/D |
128,693 |
195,874 |
|
- |
|
| Friedmann Nadav |
Chief Operating Officer |
• • – |
2014-07-01 |
4 |
D |
$5.76 |
$614,419 |
D/D |
(106,670) |
364,893 |
|
- |
|
| Friedmann Nadav |
Chief Operating Officer |
• • – |
2014-07-01 |
4 |
OE |
$4.54 |
$614,416 |
D/D |
135,334 |
471,563 |
|
- |
|
| Gussin Robert Z |
Director |
– • – |
2014-05-27 |
4 |
D |
$4.93 |
$192,610 |
D/D |
(39,069) |
27,360 |
|
- |
|
| Gussin Robert Z |
Director |
– • – |
2014-05-27 |
4 |
OE |
$4.49 |
$192,608 |
D/D |
42,897 |
66,429 |
|
- |
|
83 Records found
|
|
Page 4 of 4 |
|
|
1.45 (6.3%) 
